Anebulo Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Anebulo Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Anebulo Pharmaceuticals Inc recorded a cumulative net loss of $-8 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -68.96%.

However, within the Healthcare sector 734 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 4161 to 4789.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter	(Mar 31 2025) III. Quarter	(Dec 31 2024) II. Quarter
Y / Y Total Assets Change	-40.52 %	333.6 %	198.19 %	133.64 %	111.2 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-8	-8	-8	-8	-8
Return On Assets (TTM)	-68.96 %	-64.08 %	-76.33 %	-84.53 %	-108.07 %
ANEB's Total Ranking	# 4789	# 4161	# 4314	# 4446	# 5260
Total Assets (TTM) in million	9	11	12	14	16
Seq. Total Assets Change	-11.95 %	-11.89 %	-13.3 %	-11.57 %	541.88 %
Seq. Net Income Change	-	-	-	-	-

ANEB's 5 Years Annual ROA >> Back to ANEB Management Effectiveness >> Compare ANEB ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 333
Sector	# 735
Overall	# 4748

Return On Assets Statistics
High	Average	Low
-37.77 %	-84.48 %	-158.14 %
(Jun 30 2022)		(Sep 30 2024)

Financial Statements
Anebulo Pharmaceuticals Inc 's Assets	$ 9 million	ANEB's Balance sheet
Anebulo Pharmaceuticals Inc 's Income	$ -2 million	Quarterly ANEB's Income Statement
ANEB's Income by Division		See ANEB's Income by Division

Annual Return On Assets	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022	(Jun 30 2021) FY 2021
Y / Y Total Assets Change	198.19 %	-65.1 %	-25.09 %	-30.61 %	-
Total Assets in million	12	4	12	16	22
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-8	-8	-12	-7	-30
Annual Return On Assets	-69.86 %	-201.36 %	-100.53 %	-43.81 %	-134.75 %

ANEB's 5 Years Annual ROA >> Back to ANEB Management Effectiveness >> Compare ANEB ROA to its Competitors

More Return On Assets Ratios
ANEB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ANEB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ANEB's Competitors
Subscribers only: Roa for Anebulo Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ANEB's Customers

You may also want to know
ANEB's Roi	ANEB's Inventory Turnover Ratio	ANEB's Growth Rates	ANEB's Dividend Comparisons
	ANEB's Profitability Ratios	ANEB's Asset Turnover Ratio	ANEB's Dividend Growth
ANEB's Roe	ANEB's Valuation Ratios	ANEB's Financial Strength Ratios	ANEB's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:25:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.